Search
for

    Sort by

    Community Join

    990-1000 / 1000+ results

      community RU58841, 8% HPLC-MS done by jano, they legit

      in Research/Science  7 upvotes 4 years ago
      The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.

      community Xeljanz....the magic drug!!!

       2 upvotes 7 years ago
      A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.

      community Pyrilutamide vs topical finasteride

      in Finasteride/Dutasteride  2 upvotes 1 year ago
      The user is considering switching to topical finasteride or pyrilutamide to stabilize hair loss before a hair transplant, currently using oral minoxidil and finasteride. Suggestions include sticking to the current regimen as it is already potent, and caution against using pyrilutamide from unreliable sources.

      community Early impressions Rootique Dou + Ulo low dose finasteride

      in Technology  2 upvotes 1 month ago
      A user shares their positive experience using the Rootique Dou applicator with 0.005% finasteride, noting it effectively delivers the product without greasiness and helps with hair regrowth without side effects. Another user reports regrowth using low-dose finasteride from ULO, while avoiding tretinoin due to skin irritation.

      community Pyrilutamide phase III clinical trial results released

      in Research/Science  31 upvotes 2 years ago
      Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.